The study evaluated adherence to topical testosterone therapy in a real-world cohort of commercially insured males with primary or secondary hypogonadism. This article is written live from the ...
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establishes an exclusive telehealth co-marketing ...
AUSTIN, Texas — Fewer than one in five hypogonadal men are adherent to prescribed topical testosterone, new research indicates. The findings, from a large commercial insurance database, were presented ...
INDIANAPOLIS, June 28, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that Axiron® ...
MedPage Today on MSN
Not Enough Men On Testosterone Get Guideline-Based Hypogonadism Work-Up
Data highlight "quite a discrepancy in testosterone prescribing practice," researcher says ...
Findings compared with exercise therapy alone or usual care among older women. (HealthDay News) — Topical testosterone therapy does not significantly improve functional outcomes beyond supervised ...
INDIANAPOLIS, April 1, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States.
INDIANAPOLIS, IN and MELBOURNE, AUSTRALIA -- Eli Lilly and Company (NYSE:LLY) and Acrux (ASX: ACR) announced that the U.S. Food and Drug Administration (FDA) has approved Axiron® (testosterone) ...
Increasing the testosterone levels of female cancer survivors using testosterone cream did not improve their libido more than a placebo, according to a randomized controlled clinical trial in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results